A Multicenter Study to Clarify the Optimal Period of Combined Therapy with Pegylated Interferon plus Ribavirin in Patients with Chronic Hepatitis Caused by HCV.

A Multicenter Study to Clarify the Optimal Period of Combined Therapy with Pegylated Interferon plus Ribavirin in Patients with Chronic Hepatitis Caused by HCV. - A Study on Combined Therapy with Pegylated Interferon plus Ribavirin in Patients with Chronic Hepatitis C.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009056

Enrollment

100

Registered

2012-10-06

Start date

2012-10-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

prolongation of the treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with hepatitis C

Exclusion criteria

Exclusion criteria: pregnant patients

Design outcomes

Primary

Measure	Time frame
sustained virological response	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026